Haftungsausschluss: Diese Website bündelt öffentlich verfügbare Daten aus offiziellen Quellen wie FDA, ClinicalTrials.gov, PubMed und SEC EDGAR nur zur allgemeinen Information. Sie stellt keine medizinische Beratung, Diagnose, Behandlungsempfehlung oder Anlageberatung dar.

Klinische Studie

Efficacy and Safety of NasoAid® After Nasal Surgery

NCT: NCT07861061 · RECRUITING

NCT-IDNCT07861061
Medizinische Daten: StatusRECRUITING
Startdatum2026-08-24
Abschluss2027-07-31
SponsorMaxigen Biotech Inc. (INDUSTRY)
First posted
Last updated

Kurzzusammenfassung

The goal of this clinical trial is to evaluate the effectiveness and safety of collagen-based absorbable nasal packing (NasoAid®) after nasal surgery. The main question it aims to answer are: * The hemostasis 2, 12, 24, 48 hours after nasal packing. * The endoscopic nasal assessments scores. * The remnant percentage of nasal packing material. * Patient-reported Visual Analog Scale (VAS) scores for general assessment. * Patient-reported outcomes, including the Sino-Nasal Outcome Test-22 (SNOT-22), Nasal Obstruction Symptom Evaluation (NOSE), and Total Nasal Symptom Score (TNSS). * The incidences of safety indicators. Participants will be randomized into either experiment group or control group, receive nasal packing at Day0, and re-visited on week 1, 2, 4, 8 and 12 after nasal surgery. Researchers will compare if NasoAid® is non-inferiority to NasoPore.

Offizielle Quelle

Auf ClinicalTrials.gov ansehen →

Daten aus der ClinicalTrials.gov-API. Den aktuellsten Status finden Sie im offiziellen Eintrag.

↑